Cabot Corporation Announces Changes to Board of Directors
15 Setembro 2023 - 1:52PM
Business Wire
Cabot Corporation (NYSE: CBT) announced today that Michelle
Williams, Ph.D., has been elected to its Board of Directors,
effective September 13, 2023. She was also appointed a member of
the Audit Committee of the Board of Directors, effective September
13, 2023. Prior to her retirement in 2021, Dr. Williams was Global
Group President of Altuglas International, a manufacturer of
polymethyl methacrylate (PMMA) and a subsidiary of Arkema S.A., a
manufacturer of specialty chemicals and advanced materials. Dr.
Williams has been a Director of Brady Corporation, a manufacturer
and supplier of identification solutions and workplace safety
products, since 2019, where she serves as Chair of the Technology
Committee and a member of the Management Development and
Compensation and Corporate Governance Committees.
Sue H. Rataj, Non-Executive Chair of Cabot’s Board of Directors,
said, “We are very pleased to welcome Michelle to our Board. Her
extensive experience and business leadership roles in strategy,
commercial and operational excellence, new business development,
and innovation across diverse specialty chemicals and advanced
materials industries provides the Board with important expertise
and perspective that will further enhance the Board’s depth of
expertise and capabilities that are necessary to oversee the
Company’s Creating for Tomorrow strategy.”
“I am delighted and honored to join the Cabot Board of
Directors. Cabot is a company with exceptional products and
technologies and has many exciting opportunities for growth in the
years ahead. I look forward to drawing on my experience to help
Cabot achieve its growth objectives and further advance the
Company’s strategy,” said Dr. Williams.
With Dr. Williams’ election to the Board, Sue Rataj advised the
Company that she would be retiring from the Board effective May 31,
2024. Ms. Rataj has served as a director of Cabot since 2011. In
addition to her role as Non-Executive Chair, which she has held
since March 2018, Ms. Rataj currently serves as Chair of the
Governance and Nominating and the Executive Committees. To ensure a
smooth leadership transition, Ms. Rataj will step down as
Non-Executive Chair effective October 1, 2023, and will remain
Chair of the Governance and Nominating and Executive Committees
until her retirement from the Board. Michael Morrow, who has served
as a director of Cabot since 2017 and who currently serves as Chair
of Cabot’s Audit Committee, has been elected Non-Executive Chair of
the Board effective October 1, 2023. With these appointments,
effective October 1, 2023, Mr. Morrow will step down as Chair and a
member of the Company’s Audit Committee, and Frank (“Andy”) Wilson
has been elected Chair of the Audit Committee. Mr. Wilson will also
join the Company’s Governance and Nominating Committee at this
time.
“The Board is pleased to announce this Board leadership
succession. Mike’s financial and accounting expertise, significant
leadership, business and corporate governance experience, and
strategic business focus make him well suited for this role,” said
Sean Keohane, President and Chief Executive Officer of Cabot
Corporation. “In addition, on behalf of our Board of Directors and
management leadership team, I want to thank Sue for the dedication
and leadership she has shown as Chair and a member of the Board. We
have benefited greatly from Sue’s substantial leadership and
strategic planning experience, her business acumen, and her deep
knowledge of the chemicals industry and industrial manufacturing
operations. We will miss her insight and leadership, and we wish
her the best in her retirement,” said Keohane.
About Cabot Corporation
Cabot Corporation (NYSE: CBT) is a global specialty chemicals
and performance materials company headquartered in Boston,
Massachusetts. The company is a leading provider of reinforcing
carbons, specialty carbons, battery materials, engineered elastomer
composites, inkjet colorants, masterbatches and conductive
compounds, fumed metal oxides and aerogel. For more information on
Cabot, please visit the company’s website at cabotcorp.com. The
Company encourages investors and potential investors to consult the
Cabot website regularly.
Forward-Looking Statements – This release contains
forward-looking statements. All statements that address
expectations or projections about the future, including with
respect to the Company’s strategy and opportunities for growth, are
forward-looking statements. These statements are not guarantees of
future performance and are subject to risks, uncertainties,
potentially inaccurate assumptions, and other factors, some of
which are beyond our control and difficult to predict. If known or
unknown risks materialize, or should underlying assumptions prove
inaccurate, our actual results could differ materially from past
results and from those expressed or implied by forward-looking
statements. Important factors that could cause our results to
differ materially from those expressed or implied in the
forward-looking statements include, but are not limited to,
disruption to our operations from the COVID-19 pandemic, industry
capacity utilization and competition from other specialty chemical
companies; safety, health and environmental requirements and
related constraints imposed on our business; regulatory and
financial risks related to climate change developments; volatility
in the price and availability of energy and raw materials,
including with respect to the Russian invasion of Ukraine; a
significant adverse change in a customer relationship or the
failure of a customer to perform its obligations under agreements
with us; failure to achieve growth expectations from new products,
applications and technology developments; failure to realize
benefits from acquisitions, alliances, or joint ventures or achieve
our portfolio management objectives; unanticipated delays in, or
increased cost of site development projects; negative or uncertain
worldwide or regional economic conditions and market opportunities,
including from trade relations, global health matters or
geo-political conflicts; litigation or legal proceedings; tax rates
and fluctuations in foreign currency exchange and interest rates;
and the accuracy of the assumptions we used in establishing
reserves for our share of liability for respirator claims. These
factors are discussed more fully in the reports we file with the
Securities and Exchange Commission (“SEC”), particularly under the
heading “Risk Factors” in our annual report on Form 10-K for our
fiscal year ended September 30, 2022, filed with the SEC at
www.sec.gov. We assume no obligation to provide revisions to any
forward-looking statements should circumstances change, except as
otherwise required by securities and other applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230914860625/en/
Investor: Steve Delahunt Vice President, Treasurer and Investor
Relations (617) 342-6255
Cabot (NYSE:CBT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cabot (NYSE:CBT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024